PDUFA date for povetacicept accelerated approval in IgA nephropathy
The FDA is due to decide by Nov 30, 2026 whether to approve Vertex’s povetacicept (dual BAFF/APRIL inhibitor) for IgA nephropathy (accelerated approval). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Vertex Pharmaceuticals Incorporated VRTX
- Drug
- povetacicept (dual BAFF/APRIL inhibitor)
- For
- IgA nephropathy (accelerated approval)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Nov 30, 2026
- Source note
- FDA accepted the BLA (announced June 1, 2026) with a PDUFA target action date of November 30, 2026, supported by the prespecified Week-36 RAINIER interim analysis (52% UPCR reduction). Breakthrough Therapy designation in IgAN.
- Checked
- Checked by a person when it was added
- Source: news.vrtx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- VRTX headlines on this site
Vertex expects to report results from its Phase 2 study of inaxaplin (VX-147) for APOL1-mediated kidney disease with moderate proteinuria and with Type 2 diabetes in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.
More details
- Entry
- Inaxaplin Phase 2 AMPLIFIED data in AMKD (fall 2026) · Clinical trial results (readout / topline data)
- Drug
- inaxaplin (VX-147)
- For
- APOL1-mediated kidney disease with moderate proteinuria and with Type 2 diabetes
- Stage
- Phase 2 · the stage that tests whether the drug actually works
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Vertex Q2 2026 release: enrollment and dosing complete in AMPLIFIED; 'on track to share data this fall' (fall 2026).
- Checked
- Checked by a person when it was added
- Verify it
- Source: news.vrtx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VRTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex expects to report results from its Phase 1/2 study of VX-828 for Cystic fibrosis in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.
More details
- Entry
- VX-828 next-generation CF corrector study results · Clinical trial results (readout / topline data)
- Drug
- VX-828
- For
- Cystic fibrosis
- Stage
- Phase 1/2 · an early study that checks safety and takes a first look at effect
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Aug 3, 2026 Q2 release: dosing completed in the VX-828 study; results expected in H2 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VRTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Updated program timelines for zimislecel and VX-017 later in 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Vertex (Zimislecel (VX-880) / VX-017 for Type 1 diabetes): a step in the program rather than a decision or a data readout.
More details
- Entry
- Updated program timelines for zimislecel and VX-017 later in 2026 · Company milestone
- Drug
- Zimislecel (VX-880) / VX-017
- For
- Type 1 diabetes
- Stage
- Phase 2/3 · a combined mid- to late-stage study
- When
- H2 2026 · the company gave a window, not a day
- Source note
- Q2 2026 release (Aug 3): no BLA/MAA submission date given for zimislecel; company expects to provide updated timelines later in 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: crisprmedicinenews.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VRTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex presents data on ALYFTREK / TRIKAFTA / CF pipeline for Cystic fibrosis at a medical meeting in Oct 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
More details
- Entry
- Vertex CF portfolio abstracts at North American Cystic Fibrosis Conference · Data presented at a medical meeting
- Drug
- ALYFTREK / TRIKAFTA / CF pipeline
- For
- Cystic fibrosis
- Stage
- Various
- When
- Oct 2026 · the company gave a window, not a day
- Source note
- Q2 2026 release flags multiple CF abstracts submitted for NACFC in October 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: crisprmedicinenews.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VRTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Vertex expects to report results from its Phase 2/3 study of inaxaplin (VX-147) for APOL1-mediated kidney disease in Q4 2026 (Oct–Dec) (no exact date yet). Phase 2/3 is a combined mid- to late-stage study.
More details
- Entry
- Inaxaplin Phase 3 AMPLITUDE interim analysis in AMKD · Clinical trial results (readout / topline data)
- Drug
- inaxaplin (VX-147)
- For
- APOL1-mediated kidney disease
- Stage
- Phase 2/3 · a combined mid- to late-stage study
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Vertex guides that interim-analysis data are expected in 'late 2026 or early 2027' (could slip into 2027-H1); AMPLITUDE full enrollment on track for H2 2026. Positive interim could support an accelerated approval filing.
- Checked
- Checked by a person when it was added
- Verify it
- Source: news.vrtx.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VRTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Suzetrigine DPN Phase 3 enrollment completion by end of 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Vertex (Suzetrigine (JOURNAVX) for Diabetic peripheral neuropathy): a step in the program rather than a decision or a data readout.
More details
- Entry
- Suzetrigine DPN Phase 3 enrollment completion by end of 2026 · Company milestone
- Drug
- Suzetrigine (JOURNAVX)
- For
- Diabetic peripheral neuropathy
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- Q4 2026 · the company gave a window, not a day
- Source note
- Q2 2026 release; enrollment completion (not readout) in both DPN Phase 3s guided to year-end 2026. VX-993 Phase 2 DPN enrollment also guided to year-end 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: biospace.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- VRTX headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page